London, United Kingdom–(Newsfile Corp. – October 25, 2024) – Edison issues report on Northern Data Group (FSE: NB2)
Northern Data is a diversified provider of artificial intelligence (AI) and high-performance computing (HPC) solutions. The group has successfully expanded into generative AI cloud services and liquid-cooled data centre infrastructure, while maintaining its technological heritage. With the largest AI hardware cluster in Europe and specialised data centres, Northern Data is poised to capitalise on the substantial opportunity within the generative AI market, where demand currently outstrips supply. Its elite partnership with NVIDIA positions it as the European torch bearer for the most innovative and cutting-edge generative AI hardware and housing currently on the market.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website, www.edisongroup.com.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
enquiries@edisongroup.com
+44 (0)20 3077 5700
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227787
Toronto, Ontario--(Newsfile Corp. - December 27, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…
RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ:…
CHONGQING, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired…
MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases…
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without…
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…